Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: CCRT with weekly docetaxel & cisplatin
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT01126008
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain
Phase 3
Completed
- Conditions
- Thyroid CarcinomaThyroidectomy
- Interventions
- Drug: Usage of Fibrin sealantProcedure: Thyroidectomy
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 78
- Registration Number
- NCT01126060
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer
Phase 3
Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- Radiation: late CCRTRadiation: early CCRT
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 222
- Registration Number
- NCT01125995
- Locations
- 🇰🇷
Asan Medican Center, Seoul, Korea, Republic of
🇰🇷Keunchil Park, Seoul, Korea, Republic of
The Effect of Bevacizumab on the Trabeculectomy
Phase 2
- Conditions
- Glaucoma
- Interventions
- Drug: intraocular injections of bevacizumab
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01122966
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia
- Conditions
- Patients Receiving Induction/Consolidation ChemotherapyPatients With Acute Myeloid Leukemia
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT01106144
- Locations
- 🇰🇷
Samsung Medical Center IRB, Seoul, South Korea, Korea, Republic of
Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT
Phase 1
Terminated
- Conditions
- Phase I: To Determine the Maximum Tolerated Dose (MTD)Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin
- Interventions
- Drug: Oxaliplatin, S-1, radiotherapy
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01106066
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT01099514
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
Phase 1
Completed
- Conditions
- Metastatic Gastric Cancer
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT01099527
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT01099540
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients
- First Posted Date
- 2010-04-06
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 207
- Registration Number
- NCT01099085
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath